Table 2 Patient characteristics of patients enrolled in pazopanib based trials (n = 44)

From: Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Characteristic

Value

Sex, No.

 Male

27

 Female

17

 Age

 

 Range

14–77 years

 Median

32.5 years

ECOG performance status, No.

 0

7

 1

35

 2

2

Bone sarcoma, No. (%)

 Ewing

11 (25%)

 Osteosarcoma

5 (11%)

 Chondrosarcoma

2 (5%)

Soft tissue sarcoma, No. (%)

 Leiomyosarcoma

6 (14%)

 Alveolar soft part sarcoma

3 (7%)

 Liposarcoma

2 (5%)

 Others

15 (34%)

Prior pazopanib, No.

 Yes

5

 No

39

No. of metastatic sites, No.

 0

1

 1

20

 2

17

 3

4

 4

2

  1. ECOG: Eastern Cooperative Oncology Group.
Back to article page